Pre-made Guselkumab biosimilar ( Whole mAb, anti-IL23A therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-255
Anti-IL23A therapeutic antibody (Pre-made Guselkumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL23A therapeutic antibody (Pre-made Guselkumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||4m6m:HL/4m6n:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Janssen Biotech;MorphoSys;Taiho Pharmaceutical|
|Conditions Approved||Erythrodermic psoriasis;Palmoplantar pustulosis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis|
|Conditions Active||Crohn's disease;Hidradenitis suppurativa;Ulcerative colitis;Familial adenomatous polyposis;Psoriasis;Giant cell arteritis;Lupus nephritis;Systemic scleroderma|
|Conditions Discontinued||Rheumatoid arthritis|
|Development Tech||MorphoSys HuCAL Phage Display|